1. Home
  2. LEN vs ONC Comparison

LEN vs ONC Comparison

Compare LEN & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lennar Corporation

LEN

Lennar Corporation

HOLD

Current Price

$89.07

Market Cap

31.0B

ML Signal

HOLD

ONC

BeiGene Ltd. American Depositary Shares

HOLD

Current Price

$309.60

Market Cap

31.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LEN
ONC
Founded
1954
2010
Country
United States
Switzerland
Employees
N/A
12000
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.0B
31.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LEN
ONC
Price
$89.07
$309.60
Analyst Decision
Sell
Strong Buy
Analyst Count
15
12
Target Price
$97.77
$374.75
AVG Volume (30 Days)
3.6M
187.3K
Earning Date
03-12-2026
05-06-2026
Dividend Yield
2.25%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$747.23
Revenue Next Year
$4.41
$15.78
P/E Ratio
$15.20
$614.06
Revenue Growth
N/A
N/A
52 Week Low
$83.03
$227.40
52 Week High
$144.24
$385.22

Technical Indicators

Market Signals
Indicator
LEN
ONC
Relative Strength Index (RSI) 40.09 54.97
Support Level $83.03 $307.93
Resistance Level $124.94 $320.35
Average True Range (ATR) 3.37 7.68
MACD 0.73 4.77
Stochastic Oscillator 51.23 82.89

Price Performance

Historical Comparison
LEN
ONC

About LEN Lennar Corporation

Lennar is one of the largest public homebuilders in the United States. The company's homebuilding operations target first-time, move-up, active adult, and luxury homebuyers mainly under the Lennar brand name. Lennar's financial-services segment provides mortgage financing and related services to its homebuyers. Miami-based Lennar is also involved in multifamily and single-family for-rent construction and has invested in numerous housing-related technology startups.

About ONC BeiGene Ltd. American Depositary Shares

BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.

Share on Social Networks: